Management

Alnylam has assembled a team of passionate leaders from the biopharmaceutical industry bringing together their collective experiences of drug discovery, drug development, and commercialization.

John Maraganore, Ph.D., Chief Executive Officer

John Maraganore joined Alnylam in December 2002, bringing over 20 years of experience in Research and Development, and business roles with biotechnology companies. Prior to Alnylam he served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company's product franchises in Oncology, Cardiovascular, Inflammation, and Metabolic Diseases. He was previously Vice President, Strategic Planning and M&A and prior to that he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. (now Biogen Idec, Inc.). At Biogen, Dr. Maraganore invented and led the discovery and development of Angiomax^™ (bivalirudin for injection, formerly Hirulog^™) currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and The Upjohn Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. Dr. Maraganore is Chairman of Regulus Therapeutics, LLC, and a Director for Archemix, Inc., and Macrogenics, Inc. He is also a member of the Research Advisory Board of the Beth Israel Deaconess Hospital and a member of the Biotechnology Industry Organization Board.

Barry Greene, President and Chief Operating Officer

Barry Greene joined Alnylam in September 2003, and brings over 20 years of experience in healthcare, pharmaceutical, and biotechnology industries. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company's global strategy and execution for its oncology business including strategic business direction and execution, culminating in the successful approval and launch of VELCADE^™ (bortezomib) in mid 2003. Prior to joining Millennium in February 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene's past experiences include Vice President of Marketing and Customer Services for AstraZeneca formerly AstraMerck; Vice President Strategic Integration with responsibility for the AstraZeneca North American post merger integration; and Partner, Andersen Consulting responsible for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene received his B.S. in Industrial Engineering from University of Pittsburgh and serves as Senior Scholar at Duke University, Fuqua School of Business. Barry also serves on the Board of Acorda Therapeutics, Inc. and Regulus Therapeutics, LLC.

Laurence Reid, Ph.D., Senior Vice President, Chief Business Officer

Dr. Reid brings to Alnylam over 20 years of business development and strategic planning experience within the global biotechnology industry. During his tenure at Ensemble Discovery, he led the development and implementation of key business strategies for the company's therapeutic and diagnostic portfolios, as well as executed major therapeutic discovery alliances with Bristol-Myers Squibb and Pfizer. Prior to that, Dr. Reid worked as a founder of two start-up companies in the fields of stem cell therapeutics and inflammation. He previously spent ten years at Millennium Pharmaceuticals, where he had worked in a range of general management and business development positions. Roles included General Manager of Millennium UK with responsibility for Millennium's European operations, Vice President of Business Development and Strategic Planning for the company's predictive medicine efforts, as well as in pharmaceutical business development and technology acquisition. Before joining Millennium, he was an assistant editor of the journal Cell. Dr. Reid received his Ph.D. from London University and his B.A. from Cambridge University.

Akshay Vaishnaw, M.D., Ph.D., Senior Vice President and Chief Medical Officer

Dr. Vaishnaw comes to Alnylam from Biogen, Inc. (now Biogen Idec Inc.), where he was most recently Senior Director, Translational Medicine. In his seven years at Biogen he was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (Amevive^™) for psoriasis. Dr. Vaishnaw received his M.D. from the University of Wales College of Medicine, U.K., with Distinctions in Pathology and Medicine, and his Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Member of the Royal College of Physicians, U.K., and received an Executive M.B.A. from Harvard Business School. In addition, Dr. Vaishnaw has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease.

Steve Bossone, Ph.D., Vice President, Intellectual Property

Dr. Bossone joins Alnylam from Shire HGT with over 15 years of experience in the biotech industry. As a Senior Patent Attorney at Shire he provided licensing, acquisition and litigation support as well as strategic input into the life cycle management of several marketed products. He began his career at Millennium Pharmaceuticals as a Scientist in the oncology group and then at Millennium Biotherapeutics where he headed the transcript profiling group to support drug discovery initiatives. He transitioned to the Intellectual Property field with positions of increasing authority at Millennium, ToleRx, Serono and Shire. He received his PhD in Molecular Pathology from the lab of Dr. Kenneth Marcu at SUNY Stony Brook (NY) and subsequently worked as a Research Fellow in Medicine in the lab of Dr. Vikas Sukhatme at Harvard Medical School and Beth Israel Hospital. Steve received his JD from Suffolk University School of Law.

Cynthia Clayton, Vice President, Investor Relations and Corporate Communications

Cynthia Clayton joined Alnylam in 2005, where she leads investor and media relations, as well as corporate communications and digital strategies. Prior to joining Alnylam, Ms. Clayton was Director, Investor Relations and Corporate Communications at Synta Pharmaceuticals. In addition, as Senior Manager, Investor and Corporate Communications at Millennium Pharmaceuticals, she worked as part of the team driving the company's strategic communications initiatives, including its first product launch, Velcade. Ms. Clayton began her career in Investor Relations and Corporate Communications at Curis. She earned her B.A. with honors in Communications from the University of Hartford in Connecticut.

David Konys, Vice President, Manufacturing Operations

Mr. Konys joined Alnylam in April 2003. He was formerly Vice President of Corporate Development at Ingenium Pharmaceuticals AG, and prior to that, had over 15 years of experience at Biogen, Inc. (now Biogen Idec Inc.), where he was the 1995 recipient of the Chairman's Award. During his career, Mr. Konys has been responsible for a wide array of activities related to the building and expansion of growing biotech companies, including establishing a wholly owned subsidiary, Biogen Canada, Inc., for which he was President & Managing Director, licensing intellectual property, directing the expansion of operations groups, and marketing.

Susanna High, Vice President, Business Planning and Program Management

Ms. High joined Alnylam in February 2007 as Senior Director, Business Planning and Program Management. Ms. High joined Alnylam from Millennium Pharmaceuticals, Inc., where she most recently was Director of Corporate Strategy and prior to that Director of Business Operations. From 1996 to 2001 Ms. High held a leadership role as management consultant with Accenture in their Strategy Pharmaceutical Practice. Ms. High has more than 15 years of operations, strategic and financial management experience, locally and internationally. She holds a degree in Economics and Business from Universita' Bocconi, Milan, Italy and a Masters in Business Administration from MIT.

Muthiah (Mano) Manoharan, Ph.D., Senior Vice President, Drug Discovery

Dr. Manoharan was the former Executive Director of Medicinal Chemistry at Isis Pharmaceuticals, Inc., a leading biotechnology company focused on nucleic acid-based therapeutics where he had a 12-year tenure. With a distinguished career as a world-leading nucleic acid and bioconjugate chemist, Dr. Manoharan is an author on over 130 publications and over 200 abstracts, as well as the inventor on over 115 issued U.S. patents. Prior to Isis Pharmaceuticals, he earned his Ph.D. in chemistry at the University of North Carolina-Chapel Hill and conducted post-doctoral work at Yale University and the University of Maryland.

Michael Mason, Vice President Finance and Treasurer

Mr. Mason joined Alnylam in 2005 as Corporate Controller, and has served in roles of increasing financial and operational responsibility since that time. Prior to Alnylam, Mike was at Praecis Pharmaceuticals for five years, most recently as Corporate Controller. He began his career in financial management at KPMG LLP in 1997 where he worked with a variety of public and private audit clients. Mr. Mason received his Masters of Business Administration from Babson College and his Bachelors of Business Administration from Stetson University. Mr. Mason is a Certified Public Accountant.

Rachel Meyers, Ph.D., Vice President, Research and RLD

Dr. Meyers joined Alnylam in April of 2003 as Associate Director of Research, after having served as a Senior Scientist at Millennium Pharmaceuticals (1999-2003). At Millennium Pharmaceuticals, Dr. Meyers was involved in target advancement and the identification, bioinformatic analysis, cloning and functional analysis of novel targets for small molecule drug discovery, antibody development and diagnostic purposes. At Alnylam, Dr. Meyers oversees the RLD and immunology groups and plays a key role in the development of Alnylam's RNAi therapeutic programs. Dr. Meyers holds a degree in Biochemistry from Brandeis University and a Ph.D. in Biology from MIT, and she completed her post-doctoral training at Harvard Medical School. Dr. Meyers is a member of the advisory board for the MS program in Biotechnology at Brandeis University.

Saraswathy (Sara) Nochur, Ph.D., Vice President, Regulatory Affairs

Dr. Nochur has over 19 years of experience in the areas of product development and regulatory affairs. Most recently, she held the position of Vice President, Regulatory Affairs at The Medicines Company. Prior to her four years there, she served as Director, Product Development and Regulatory Affairs for CereMedix, Inc. Dr. Nochur also held senior positions at BioTrack, Inc. including Vice President, Product Development and Regulatory Affairs, and Chief Operating Officer. Prior to that she was employed by DynaGen, Inc. where she held positions of increasing responsibility, culminating in the role of Director, New Product Development. Dr. Nochur received her B.S. and M.S. degrees in Microbiology from the University of Bombay in India, and her Ph.D. in Biochemical Engineering at MIT.

Eric Raichle, Vice President, Human Resources

Mr. Raichle joins Alnylam with over 20 years of global human resources experience with expertise in employee relations, talent management, communication and organizational development. He has contributed to the success of several public and private companies including Bain & Company, Digitas LLC, and most recently served as the Director of Human Resources at Alkermes, Inc. He holds a B.A. in Industrial and Organizational Psychology from Suffolk University.

Dinah Sah, Ph.D., Vice President, Research, CNS, and Oncology

Dr. Sah joined Alnylam in April 2005 as Senior Director, Research, and was promoted to Vice President, Research, CNS and Oncology, in 2008. She has over 17 years of experience in research and development in the biotechnology industry. Before joining Alnylam, Dr. Sah served as Associate Director, Research, at Biogen (now Biogen Idec), where she led neuroscience research, strategic planning for the neurobiology focus area, and several research projects. Prior to her 6 years at Biogen, she was employed by Signal Pharmaceuticals, where she headed neuroscience research and was the leader of multiple corporate partnerships and projects. At Alnylam, Dr. Sah oversees the CNS, oncology and metabolic research groups, as well as several delivery teams. She plays a primary role in advancing Alnylam's therapeutic RNAi programs, having served as program leader for the liver cancer and TTR amyloidosis programs from research into Phase I, as well as the Huntington's Disease program in collaboration with Medtronic. Dr. Sah received a B.S. in Biology from the Massachusetts Institute of Technology, a Ph.D. in Neurobiology from Harvard University, and her post-doctoral training at Harvard Medical School.

Garvin Warner, Ph.D., Vice President, Pre-Clinical Development

Dr. Warner joined Alnylam in August of 2010 and has over 19 years of experience in nonclinical drug development. Dr. Warner spent 13 years at Genetics Institute/Wyeth, most recently as an Assistant Vice President/Wyeth Fellow and Therapeutic Area Head within the department of Drug Safety and Metabolism responsible for the immunology and vaccine therapeutic areas. Prior to his role as Therapeutic Area Head, Dr. Warner managed the Exploratory Toxicology group and was the Andover site head for the Drug Safety and Metabolism group. Prior to joining Genetics Institute/Wyeth Dr. Warner was Group Leader of Immunotoxicology within the Department of Biologics Evaluation at Bristol-Myers Squibb. During his career in the pharmaceutical industry, Dr. Warner has been closely involved in all phases of nonclinical drug development and in the successful nonclinical development of 7+ marketed therapeutic proteins/vaccines. Dr. Warner received his Ph.D. in Microbiology and Immunology from Albany Medical College and his A.B. from Colgate University.